ghrelin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-12 and is reviewed periodically as new material appears.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
By interchanging the Arg-1, Lys-3, and Asp-8 residues to see if their positions are essential for sodium channel binding or formation of the secondary structure, inactive peptides were obtained which proposes that correct positioning of these residues is critical for activity. The introduction of disulfide bonds in the kink structure to make it less flexible also led to inactive peptides as they appeared to be very sensitive to structural changes. However, a peptide where Lys-3 was replaced with a more basic Arg residue showed better activity. This was designed based on observations that some of the acidic residues in the neuronal sodium channels are important for binding and that removal of basic residue Lys-3 from α-PMTX was not tolerated, while removal of acidic residue Asp-8 was. By combining K3R (lysine-3 to arginine) and S11L (serine-11 to leucine) mutations, a higher activity could also be obtained. Lipophilic residues in other toxins that block sodium channels have been assumed to be important for binding at site 3 of neuronal sodium channels. Additionally, it was found that replacing Phe-7 of β-PMTX with more lipophilic amino non-natural amino acids such as 1-Nal and 2-Nal resulted in a boost in activity, while replacement with a polar residue led to a complete loss of activity. This suggests an essential role of the endogenous Phe-7 residue in mediating the interaction between the venom toxin and the sodium channel.
In the 1497 expedition of Vasco da Gama, the curative effects of citrus fruit were known. In the 1500s, Portuguese sailors put in to the island of Saint Helena to avail themselves of planted vegetable gardens and wild-growing fruit trees. Authorities occasionally recommended plant food to prevent scurvy during long sea voyages. John Woodall, the first surgeon to the British East India Company, recommended the preventive and curative use of lemon juice in his 1617 book, The Surgeon's Mate. In 1734, the Dutch writer Johann Bachstrom gave the firm opinion, "scurvy is solely owing to a total abstinence from fresh vegetable food, and greens." Scurvy had long been a principal killer of sailors during the long sea voyages. According to Jonathan Lamb, "In 1499, Vasco da Gama lost 116 of his crew of 170; In 1520, Magellan lost 208 out of 230; ... all mainly to scurvy."
Kava reduces short-term, situational anxiety, but its specific efficacy for generalized anxiety disorder appears to not be supported by the evidence. Many countries banned or restricted kava in 2002 due to safety concerns. The World Health Organization (WHO) subsequently reviewed kava's safety and concluded that moderate consumption of kava in its traditional form, as a water-based suspension of roots, presents an "acceptably low level of health risk". However, WHO and other health authorities have also concluded that consumption of kava extracts produced with organic solvents or excessive amounts of low-quality kava products may be linked to an increased risk of adverse health outcomes, including liver injury.
== Side effects == The US prescribing information for datopotamab deruxtecan includes warnings and precautions for interstitial lung disease/pneumonitis, ocular adverse reactions, stomatitis/oral mucositis, and embryo-fetal toxicity. Datopotamab deruxtecan is associated with a range of adverse events. The most common side effects are stomatitis, nausea, fatigue, alopecia (hair loss), constipation, vomiting, dry eye, keratitis, anemia, decreased appetite, increased aspartate transferase (AST), rash, diarrhea, neutropenia, and increased alanine aminotransferase (ALT).
Even after being expelled from the government of Peru and the Gran Colombo-Peruvian war ended, he would continue to rant against Peru and its people in multiple letters, considering them the greatest disgrace on the American continent and with a people complicit in tyranny, seeing the country as epitome of all the anarchic defects that plagued Latin America after the independences:"What men, or what demons, are these! From one end to the other, the New World seems an abyss of abomination; and if anything were lacking to complete this frightful chaos, Peru, with too much, would be enough to fill it. Accomplice of their tyrants during the War of Independence, without yet achieving its freedom, Peru anticipates tearing up its own bosom in the first days of its existence.The gallant General San Martín, at the head of the Chileans and the Argentineans, expels to the Spaniards from Trujillo to Ica. For Lima, there was no Peru but freedom, and at once some were bent on getting rid of San Martín, whose services they most urgently needed.
Sources: en.wikipedia.org
In 2014, Emerald Therapeutics spun out the Emerald Cloud Lab to fully replace the need for a traditional lab environment, enabling scientists from around the world to perform all necessary activities, from experimental design to data acquisition and analysis. Carnegie Mellon University's Mellon College of Science is building the world's first academic cloud laboratory on their campus. The 20,000 square foot laboratory will be completed in 2023 and offer access to CMU researchers and eventually to other schools and life-sciences startups in Pittsburgh.
It is revealing that thioesters are obligatory intermediates in several key processes in which ATP is either used or regenerated. Thioesters are involved in the synthesis of all esters, including those found in complex lipids. They also participate in the synthesis of a number of other cellular components, including peptides, fatty acids, sterols, terpenes, porphyrins, and others. In addition, thioesters are formed as key intermediates in several particularly ancient processes that result in the assembly of ATP. In both these instances, the thioester is closer than ATP to the process that uses or yields energy. In other words, thioesters could have actually played the role of ATP in a "thioester world" initially devoid of ATP. Eventually, [these] thioesters could have served to usher in ATP through its ability to support the formation of bonds between phosphate groups. However, due to the high free energy change of thioester's hydrolysis and correspondingly their low equilibrium constants, it is unlikely that these compounds could have accumulated abiotically to any significant extent especially in hydrothermal vent conditions.
== Clinical significance == Soft tissue disorders are medical conditions affecting soft tissue. Soft tissue injuries are some of the most chronically painful and difficult conditions to treat because it is very difficult to see what is going on under the skin with the soft connective tissues, fascia, joints, muscles and tendons. Musculoskeletal specialists, manual therapists, neuromuscular physiologists and neurologists specialize in treating injuries and ailments in the soft tissue areas of the body. These specialized clinicians often develop innovative ways to manipulate the soft tissue to speed natural healing and relieve the mysterious pain that often accompanies soft tissue injuries. This area of expertise has become known as soft tissue therapy and is rapidly expanding as technology continues to improve the ability of these specialists to identify problem areas. A promising new method of treating wounds and soft tissue injuries is via platelet-derived growth factor. There is a close overlap between the term "soft tissue disorder" and rheumatism. Sometimes the term "soft tissue rheumatic disorders" is used to describe these conditions. Soft tissue sarcomas are many types of cancer that can develop in the soft tissues.
=== Pharmacodynamic interactions === Since beta blockers are known to relax the cardiac muscle and constrict the smooth muscle, they have an additive effect with other drugs that decrease blood pressure or decrease cardiac contractility or conductivity. Pharmacodynamic interactions may occur with other drugs affecting the cardiovascular system, including propafenone, quinidine, amiodarone, cardiac glycosides, calcium channel blockers like verapamil and diltiazem, ACE inhibitors, alpha blockers like prazosin, catecholamine-depleting drugs like reserpine, ergot alkaloids, and adrenergic receptor agonists including epinephrine (adrenaline), isoprenaline (isoproterenol), dobutamine, β2-adrenergic receptor agonists like salbutamol, levosalbutamol, formoterol, salmeterol, and clenbuterol, and α2-adrenergic receptor agonists like clonidine. Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) have hypotensive side effects and these may be exacerbated by propranolol. Hypotension and cardiac arrest have been reported with the combination of propranolol and haloperidol. Nonsteroidal anti-inflammatory drugs (NSAIDs), which include drugs like ibuprofen, naproxen, and aspirin, have been reported to blunt the antihypertensive effects of beta blockers like propranolol. The NSAID indomethacin specifically may reduce the efficacy of propranolol in decreasing heart rate and blood pressure.
Onabotulinumtoxin A (trade name: Botox) received FDA approval for treatment of chronic migraines on 15 October 2010. The toxin is injected into the head and neck to treat these chronic headaches. Approval followed evidence presented to the agency from two studies funded by Allergan showing a very slight improvement in incidence of chronic migraines for those with migraines undergoing the Botox treatment. Since then, several randomized control trials have shown botulinum toxin type A to improve headache symptoms and quality of life when used prophylactically for participants with chronic migraine who exhibit headache characteristics consistent with: pressure perceived from outside source, shorter total duration of chronic migraines (<30 years), "detoxification" of participants with coexisting chronic daily headache due to medication overuse, and no current history of other preventive headache medications.
Sources: en.wikipedia.org
== Physiological effects == Catecholamines cause general physiological changes that prepare the body for physical activity (the fight-or-flight response). Some typical effects are increases in heart rate, blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous system. Some drugs, like tolcapone (a central COMT-inhibitor), raise the levels of all the catecholamines. Increased catecholamines may also cause an increased respiratory rate (tachypnoea) in patients. Catecholamine is secreted into urine after being broken down, and its secretion level can be measured for the diagnosis of illnesses associated with catecholamine levels in the body. Urine testing for catecholamine is used to detect pheochromocytoma.
=== Derivation === This section presents a derivation of the equation above for electrons. A similar derivation can be found for the equation for holes. Consider the fact that the number of electrons is conserved across a volume of semiconductor material with cross-sectional area, A, and length, dx, along the x-axis. More precisely, one can say:
It has a cyclic structure, lipophilic nature, and is enzymatically stable which makes it a more favourable candidate for manipulating the binding-release process between IGF1 and its binding protein, thereby normalising IGF1 function.
== Definition == The phrase "drug design" is similar to ligand design (i.e., design of a molecule that will bind tightly to its target). Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, and side effects, that first must be optimized before a ligand can become a safe and effective drug. These other characteristics are often difficult to predict with rational design techniques. Due to high attrition rates, especially during clinical phases of drug development, more attention is being focused early in the drug design process on selecting candidate drugs whose physicochemical properties are predicted to result in fewer complications during development and hence more likely to lead to an approved, marketed drug. Furthermore, in vitro experiments complemented with computation methods are increasingly used in early drug discovery to select compounds with more favorable ADME (absorption, distribution, metabolism, and excretion) and toxicological profiles.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.